Overview

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls with Rett syndrome
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.